S&P 500
5.064,20 +45,81 (+0,91%) Nasdaq
15.840,96 +235,48 (+1,51%) NIKKEI 225
38.236,07 -37,98 (-0,10%) Dólar/Euro
1,0730 +0,0012 (+0,11%) Petróleo Brent
83,76 +0,32 (+0,38%) Bitcoin EUR
54.860,81 +1.454,36 (+2,72%)
Acura Pharmaceuticals, Inc. (ACUR)
Acura Pharmaceuticals, Inc.
616 N. North Court
Suite 120
Palatine, IL 60067
United States
847 705 7709
https://www.acurapharm.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert B. Jones | CEO, President & Director | 150k | N/A | 1959 |
| Mr. Peter A. Clemens | Senior VP, CFO & Secretary | 200k | N/A | 1953 |
| Mr. Robert A. Seiser CPA, Ph.D. | VP, Treasurer & Corporate Controller | 210,2k | 3,24k | 1964 |
Descripción
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Gobierno corporativo
El ISS Governance QualityScore de Acura Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
